MAPS is sponsoring a Phase 2, open-label protocol to study the comparative effectiveness of two vs. three MDMA-assisted therapy sessions in Veterans with PTSD at the James J. Peters Veterans Affairs (VA) …
On November 8, 2021, MAPS submitted a new study protocol to the U.S. Food and Drug Administration (FDA) for a Phase 2 open-label feasibility and safety study of MDMA-assisted group therapy for the treatment …
MAPS is on The TODAY Show! This morning, NBC educated millions of people about psychedelic science by airing an interview with MAPS Founder Rick Doblin, Ph.D., and MDMA-assisted therapy study participants …
We are currently seeking research volunteers for our second Phase 3 clinical trial of MDMA-assisted therapy for PTSD. Volunteers must have PTSD and live in an area close to a study site. People of color …
On August 17 and 18, 2021, researchers from MAPS Public Benefit Corporation (MAPS PBC) conducted the official site initiation visit for the MAPS-sponsored Phase 2 study of MDMA-assisted therapy for U.S. …
We are currently seeking research volunteers for our second Phase 3 clinical trial of MDMA-assisted therapy for PTSD. Volunteers must have PTSD and live in an area close to a study site. Volunteers will …
We are currently seeking research volunteers for our second Phase 3 clinical trial of MDMA-assisted therapy for PTSD. Volunteers must have PTSD and live in an area close to a study site. Volunteers will …
We are currently seeking research volunteers for our second Phase 3 clinical trial of MDMA-assisted therapy for PTSD. Volunteers will help contribute to scientific knowledge and will help us better understand …
On June 11, 2021, the first participant in Be’er Ya’akov (Merhavim), Israel, was enrolled in our randomized, double-blind, placebo-controlled, multi-site Phase 3 study of the efficacy and safety of …
We are currently seeking research volunteers for our second Phase 3 clinical trial of MDMA-assisted therapy for PTSD. Volunteers will help contribute to scientific knowledge and will help us better understand …
On May 3, 2021, we announced that the first Phase 3 trial of MDMA-assisted therapy for posttraumatic stress disorder (PTSD) which replicated and expanded on Phase 2 results indicates that MDMA-assisted …
